目的 研究曲美布汀聯(lián)合氯波必利治療功能性消化不良的療效。方法 選擇2016年1月—2018年12月楊凌示范區(qū)醫(yī)院的82例功能性消化不良患者作為研究對(duì)象，用抽簽法隨機(jī)將患者分為對(duì)照組和觀察組，每組各41例。對(duì)照組服用蘋果酸氯波必利片，1片/次，3次/d。觀察組在對(duì)照組的基礎(chǔ)上飯后服用馬來(lái)酸曲美布汀片，0.2 g/次，3次/d。兩組均連續(xù)治療2周。觀察兩組患者的臨床治療效果、癥狀改善情況及胃動(dòng)力學(xué)相關(guān)指標(biāo)。結(jié)果 治療后，觀察組的總有效率為92.68%，明顯高于對(duì)照組的73.17%（P<0.05）。治療后，觀察組的腹部疼痛感、飽脹不適感、反酸、嘔吐及惡心等癥狀的改善時(shí)間明顯短于對(duì)照組（P<0.05）。治療后，兩組的胃竇收縮頻率、胃竇收縮幅度以及胃竇面積的收縮幅度均明顯升高，胃半排空時(shí)間明顯縮短（P<0.05），且觀察組胃動(dòng)力學(xué)指標(biāo)改善更為明顯（P<0.05）。治療后，兩組的腹脹、上腹痛、早飽、厭食、暖氣、燒心、惡心嘔吐、反酸評(píng)分均明顯降低（P<0.05），且觀察組癥狀評(píng)分明顯低于對(duì)照組（P<0.05）。結(jié)論 曲美布汀聯(lián)合氯波必利治療功能性消化不良具有確切的療效，能改善其癥狀和胃動(dòng)力學(xué)，具有臨床推廣應(yīng)用價(jià)值。

Objective To study the effect of trimebutine combined with clebopride in treatment of functional dyspepsia. Methods A total of 82 patients with functional dyspepsia in Yangling Demonstration Zone Hospital from January 2016 to December 2018 were selected as research objects, and randomly divided into control group and observation group, with 41 patients in each group. Patients in the control group were po administered with Clebopride Malate Tablets, 1 tablet/time, three times daily. Patients in the control group were po administered with Trimebutine Maleate Tablets on the basis of control group, 0.2 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical therapeutic effect, symptom improvement, and gastric dynamics in two groups were observed. Results After treatment, the total effective rate of the observation group was 92.68%, which was significantly higher than 73.17% of the control group (P<0.05). After treatment, the improvement time of abdominal pain, fullness and discomfort, acid reflux, vomiting and nausea in the observation group was significantly shorter than those in the control group (P<0.05). After treatment, the gastric antrum contraction frequency, the gastric antrum contraction amplitude, and the gastric antrum area in two groups were significantly increased, and the gastric half-emptying time was significantly shortened (P<0.05). And the gastric dynamics indexes in the observation group was significantly improved (P<0.05). After treatment, the scores of abdominal distension, upper abdominal pain, early satiety, anorexia, nausea and vomiting, and acid reflux were significantly reduced in two groups (P<0.05), and the score of symptoms in the observation group was significantly lower than those in the control group (P<0.05). Conclusion Trimebutine combined with clebopride in treatment of functional dyspepsia has definite curative effect, can improve its symptoms and gastric dynamics, and has clinical application value.

R975